Neurocrine Biosciences Inc

Chart & Performance

D1W1MN

P/E

38.28

P/S

5.55

EPS

3.45

Div Yield, %

—

Shrs. gr., 5y

1.61%

Rev. gr., 5y

24.48%

Revenues

2.36b

+24.81%

Net income

341m

+36.68%

CFO

595m

+52.71%

Earnings

Jul 30, 2025

Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

URL

https://www.neurocrine.com/

IPO date

May 23, 1996

Employees

1,350

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	2,355,300 24.81%	1,887,100 26.76%	1,488,700 31.34%
Cost of revenue	765,100	604,700	487,000
Unusual Expense (Income)
NOPBT	1,590,200	1,282,400	1,001,700
NOPBT Margin	67.52%	67.96%	67.29%
Operating Taxes	144,700	82,400	59,400
Tax Rate	9.10%	6.43%	5.93%
NOPAT	1,445,500	1,200,000	942,300
Net income	341,300 36.68%	249,700 61.62%	154,500 72.43%
Dividends
Dividend yield
Proceeds from repurchase of equity	(300,000)	65,300	44,700
BB yield	2.12%	-0.49%	-0.38%
Debt
Debt current		170,100	169,400
Long-term debt	910,200	516,600	187,000
Deferred revenue			(32,800)
Other long-term liabilities	166,200	106,300	29,700
Net debt	(290,700)	(1,194,300)	(1,034,400)
Cash flow
Cash from operating activities	595,400	389,900	339,400
CAPEX	(38,200)	(28,300)	(16,500)
Cash from investing activities	(126,800)	(467,100)	(177,100)
Cash from financing activities	(486,700)	65,300	(234,300)
FCF	1,175,000	1,364,200	719,700
Balance
Cash	1,076,100	1,031,600	989,300
Long term investments	124,800	849,400	401,500
Excess cash	1,083,135	1,786,645	1,316,365
Stockholders' equity	35,100	(150,000)	(414,600)
Invested Capital	3,175,900	2,916,700	2,373,200
ROIC	47.45%	45.37%	38.83%
ROCE	49.52%	46.35%	50.30%
EV
Common stock shares outstanding	103,700	101,000	98,900
Price	136.50 3.60%	131.76 10.31%	119.44 40.24%
Market cap	14,155,050 6.37%	13,307,760 12.66%	11,812,616 41.67%
EV	13,864,350	12,113,460	10,778,216
EBITDA	1,587,500	1,303,700	1,017,300
EV/EBITDA	8.73	9.29	10.59
Interest		4,600	7,100
Interest/NOPBT		0.36%	0.71%